• Received 10 purchase orders in Q2 FY25, up 150% from prior period
• Expanded commercial arrangements with Stryker into Australia and New Zealand
• Steady progress on HiRise validation for robotic surgical systems

CurveBeam AI Limited (ASX: CVB), a developer and manufacturer of specialized medical imaging (CT) equipment and AI-enabled SaaS solutions, has announced its Appendix 4C and quarterly activity report for the period ended 31 December 2024 (Q2 FY25). The company received 10 purchase orders (POs) during the quarter, representing a 150% increase over the prior corresponding period (pcp) of four POs. Five of the POs came through Stryker, and the first half of FY25 had a total of 13 POs, up almost 100% compared to the first half of FY24. Receipts from customers for Q2 FY25 were A$2.6m, up from A$2.4m in Q1 FY25. The company continued to progress the validation of the enhanced HiRise scanner for a major robotic aided surgical system, with steady progress made over the holiday period and into early 2025. The company's revised BMD regulatory strategy is to clear the first BMD module on multidetector CT (MDCT) scanners in H1 FY25, with the HiRise BMD FDA clearance targeted via a special 510(k) post the initial MDCT clearance. Cash outflows from operations for Q2 FY25 were A$2.7m, down from A$5.3m in Q2 FY24 and A$4.7m in Q1 FY25. Cash at the end of Q2 was A$8.8m, with a further A$6.0m of cash receipts expected in H2 FY25 from existing POs.

The company expects to receive a further A$6.0m in receipts from customers over H2 FY25 from existing purchase orders, before any further purchase orders in Q3 or Q4.